Sensus Healthcare Inc. (SRTS:NSD) Analysts rate with a Strong Buy, $12 target

STA Research
by: STA Research
Sensus Healthcare Inc. stock

Based on the Sensus Healthcare Inc. stock forecasts from 2 analysts, the average analyst target price for Sensus Healthcare Inc. is USD 12.20 over the next 12 months. Sensus Healthcare Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sensus Healthcare Inc. is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Sensus Healthcare Inc.’s stock price was USD 7.80. Sensus Healthcare Inc.’s stock price has changed by +0.74% over the past week, -1.35% over the past month and +129.41% over the last year.

Just recently the stock was reiterated by Maxim Group with a Buy rating and a $14, 12 month target forecast.

Sensus Healthcare, Inc. produces and distributes radiation treatment devices to healthcare providers globally. The company’s treatment devices use superficial radiation therapy (SRT), a low-energy X-ray method. Sensus Healthcare, Inc. was founded in 2010 and is based in Boca Raton.

What we like:

Superior return on equity

The company management has delivered a better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered a better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered a better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk-adjusted returns

This company is delivering below median risk-adjusted returns to its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers’ median on a price to book value basis.

Negative cash flow

The company had negative total cash flow in the most recent four quarters.

Overpriced on a free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering buying.

 

Leave a Reply

Your email address will not be published.